Interview: Ana Menéres, Managing Associate of Life Sciences, SRS Advogados,…
“The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the…
SRS Advogados was the first Portuguese law firm to establish a partnership with an international law firm, Simmons & Simmons. Their practice has expanded significantly in recent years and is now one of the largest and most highly respected in Portugal with a team of over 80 lawyers.
The SRS team advises clients on all aspects of domestic as well as international law, with particular expertise in commercial, competition, corporate, dispute resolution, employment, energy, environment, EU, finance, infrastructure, life sciences, public, real estate, regulatory, shipping, tax and TMT.
They offer their clients a strong position in the national and international market, benefiting from a presence in Lisbon, Funchal and Oporto (the latter by way of association), as well as a first rate international presence through a number of international partnerships, namely in Angola, Brazil, Macao and Mozambique
Being the leader in creating value and service for the client is their service.
Their values, focus, drive, commitment, innovation, and ambition, are the values of a team that works cohesively and with constant dedication to the client.
www.srslegal.pt
Sociedade Rebelo de Sousa & Advogados Associados, RL
LISBON
R. Dom Francisco Manuel de Melo, n.º21, 1070-085
T. + 351 21 313 2000 | F. +351 21 313 2001
FUNCHAL
Av. Zarco n.º 2, 2º, 9000-069
T. +351 29 120 2260 | F. +351 29 120 2261
OPORTO (In association with: ALC & Associados)
R. Tenente Valadim n.º 215, 4100-479
T. +351 22 543 2610 | F. +351 22 543 2611
Angola
Brazil
Macao
Mozambique
“The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the…
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three…
Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export…
Nelson Ambrogio, managing director of Bayer Portugal, talks about tthe collaboration between the industry and the government, he recent successes of his affiliate, and strategies for continued growth during the…
Servier Portugal’s general manager José Albino Mendes discusses how Portugal’s economic crisis provides real opportunities for growth, the potential for attracting talent in innovative research, and the affiliate’s recently opened…
Nuno Brás, General Manager of LEO Farmacêuticos discusses the effect of the crisis on the Portuguese pharmaceutical market, how being a small privately owned company was an advantage during the…
David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic…
Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and…
Robin Turner, General Manager of Roche Portugal, looks back on the evolution of the affiliate, and describes how the company managed to recover its debt owed by Portuguese hospitals through…
António Leão, General Manager of Lilly, Portugal, talks about adapting to a challenging economic environment, as well as the importance of the company’s portfolio and pipeline, in Portugal today. Why…
Eduardo Pinto Leite, Director General of GSK Portugal, talks about the recent Portugal bailout, how its effects pushed GSK to some tough decision, and why he sees a brighter future…
See our Cookie Privacy Policy Here
